MTOR and cancer: The authors demonstrated that heterotypic adherens junctions between cancer cells and osteoblasts or BMSCs (but not with osteoclasts) were necessary to activate the mTOR pathway in BCCs and, consequently, to elicit a proliferative response of cancer cells in the bone microenvironment, which was completely abolished if the formation of junctions was inhibited.